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Oral anticoagulant is widely used in Malaysia to prevent thromboembolic events. 
Commonly used oral anticoagulants in Hospital Putrajaya are Warfarin, Rivaroxaban 
and Dabigatran. In patient with atrial fibrillation, the risk of stroke increases to 5-fold 
in patients and use of anticoagulant therapy reduces the risk of stroke and all-cause 
mortality. Although proven to be effective, these oral anticoagulants can cause major 
bleeding. This study was carried out retrospectively in adult patients from INR Clinic 
with oral anticoagulant. The assessment parameter was incidence of major bleeding 
event. Among 113 enrolled patients, 19 had a first major bleeding event. It was found 
that age (OR 1.06; 95% CI 1.02, 1.11) and overwarfarinisation event (OR 1.91; 95% 
CI 1.26, 2.89) is significant to increase patient’s risk to major bleeding. Comorbid of 
hypertension (OR 2.66; 95% CI 0.82, 8.63), congestive heart failure (OR 2.44; 95% CI 
0.74, 8.00, renal impairment specifically stage 4 (OR 9.00; 95% CI 0.72, 113.02) and 
stage 5 (OR 6.00; 95% CI 0.42, 85.25), concomitant antiplatelet therapy (OR 0.43; 95% 
CI 0.13, 1.40), types of oral anticoagulant (novel anticoagulant vs warfarin) (OR 3.42; 
95% CI 0.42, 27.58) and TTR (OR 0.96; 95% CI 0.93, 1.00) and other factors studied 
are not significant in this study. High risk patient should be identified based on the 
factors exist in them and monitored frequently to minimize the adverse effect of 
anticoagulant. Patient with first event of major bleeding and especially elderly should 
be monitored more stringently as they may develop subsequent fatal bleed. 













TABLE OF CONTENTS………………………………………………………….....v 
LIST OF TABLES…………………………………………………………….…….vii 
LIST OF ABBREVIATIONS……………………………………………………...viii 
 
CHAPTER 1 ................................................................................................................. 1 
INTRODUCTION ................................................................................................... 1 
1.1 Background ...................................................................................................... 1 
1.2 Problem Statement ........................................................................................... 2 
1.3 Research Objectives ......................................................................................... 2 
1.4 Research Question ........................................................................................... 3 
1.5 Hypotheses To Be Tested ................................................................................ 3 
1.6 Significance of the Study ................................................................................. 3 
1.7 Scope and Limitation of Study ........................................................................ 3 
 
CHAPTER 2 ................................................................................................................. 4 
LITERATURE REVIEW ....................................................................................... 4 
2.1 Overview of oral Anticoagulant ....................................................................... 4 
2.2 Major bleeding with anticoagulant .................................................................. 7 
2.3 Risk factor for major bleeding with oral Anticoagulant .................................. 9 
2.4 Tools to Predict Bleeding Event for Patient on Oral ANticoagulant ............. 18 
 
CHAPTER 3 ............................................................................................................... 20 
RESEARCH METHODOLOGY ......................................................................... 20 
3.1 Study Design .................................................................................................. 20 
 vi 
3.2 Study Period ................................................................................................... 20 
3.3 Study Flow Chart ........................................................................................... 20 
3.5 Study Population ............................................................................................ 21 
3.6 Sampling Method ........................................................................................... 21 
3.7 Sample Selection ............................................................................................ 21 
3.8 Sampling Size Determination ........................................................................ 21 
3.9 Data Collection and Definition of Clinical Characteristics and Outcome 
Measures .............................................................................................................. 22 
3.10 Data Analysis ............................................................................................... 27 
3.11 Ethical Consideration ................................................................................... 29 
 
CHAPTER 4 ............................................................................................................... 30 
RESULTS ............................................................................................................... 30 
4.1 Patients’ Social and Clinical Demographic Data ........................................... 30 
4.2 First Major Bleeding Event among Patients on Oral Anticoagulants. ........... 33 
4.3 Relationship between Patient’s social, Clincal demographic Data and 
Anticoagulant Characteristics with major bleeding Events. ................................ 36 
 
CHAPTER 5 ............................................................................................................... 41 
DISCUSSION ......................................................................................................... 41 
5.1 Major Bleeding Events .................................................................................. 41 
5.2 Risk Factors to Major Bleeding ..................................................................... 42 
5.3 Limitations ..................................................................................................... 44 
 
CONCLUSION ...................................................................................................... 46 
REFERENCES ....................................................................................................... 47 
APPENDICES ........................................................................................................ 55 
APPENDIX A ......................................................................................................... 56 
APPENDIX B ......................................................................................................... 58 
 
 
